Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study (Herhaalde toediening van rhenium-188-HEDP versus radium-223-chloride aan patienten met gemetastaseerd castratie-resistent prostaatcarcinoom; de RaRe studie. )

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Sep 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rhenium-188-etidronic acid (Primary) ; Radium 223 chloride
Indications Bone metastases; Prostate cancer
Focus Therapeutic Use
Acronyms RaRe

Most Recent Events

28 Aug 2019 Status changed from recruiting to active, no longer recruiting.
03 Apr 2019 Clinical study design was presented at the 110th Annual Meeting of the American Association for Cancer Research.
31 Aug 2018 Biomarkers information updated

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight